In CLL, the BCR is constitutively active through ligand-dependent and independent mechanisms, causing constitutive BTK signaling activation, which confers a survival and proliferation advantage to the neoplastic cells (Figure 1) [88]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.